Exploring hepatic stellate cell-driven fibrosis: therapeutic advances and future perspectives

Review article

Authors

DOI:

https://doi.org/10.5599/admet.2874

Keywords:

Retinoid receptors, non-alcoholic fatty liver disease, resmetirom, liposomes, active targeting, clinical trials

Abstract

Background and purpose: Liver fibrosis, a progressive liver disease arising from viral or metabolic causes, poses a major global health challenge due to its potential progression to cirrhosis and hepatocellular carcinoma. Due to the complex aetiology and epidemiology of liver fibrosis, most therapies fail in the clinic, and very few drugs have been approved by the US FDA. Approach: This review highlights the patho­physiological features of liver fibrosis, with a focus on novel targets in hepatic stellate cells (HSCs), key players in the fibrogenesis process, to develop successful therapeutic approaches using both pharma­cological agents and active targeting strategies. The review also examines current therapeutic strategies targeting liver fibrosis, both in preclinical lab setups and clinical trials. Furthermore, various receptors involved in HSC-mediated liver fibrosis and active drug delivery targeting strategies are reviewed to enhance therapeutic outcomes. This article also integrates existing knowledge to identify research gaps and guide future investigations and clinical translation in liver fibrosis treatment. In addition, novel pathways pertaining to liver fibrosis, such as the RSPO3-LGR4/5-β-catenin cascade, the CD47/YAP/TEAD4 signalling axis, and HAb18G/CD147, are briefly elaborated in the context of therapeutic approaches for arresting HSC activation. Single-cell RNA sequencing of HSCs is presented to provide a clearer picture of liver fibrosis. Conclusion: The review highlights critical research gaps in liver fibrosis therapy and promising active tar­geting strategies and pharmacological interventions to improve therapeutic outcomes. Overall, this review provides a robust foundation for scientists and clinicians to advance active targeting of the disease pathology and to develop new pharmaceutical formulations that are pharmacologically safer and more efficacious.

Downloads

Download data is not yet available.

References

1. M. Zamani, S. Alizadeh-Tabari, V. Ajmera, S. Singh, M.H. Murad, R. Loomba. Global Prevalence of Advanced Liver Fibrosis and Cirrhosis in the General Population: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 23 (2025) 1123-1134. https://doi.org/10.1016/J.CGH.2024.08.020 DOI: https://doi.org/10.1016/j.cgh.2024.08.020

2. V. Tiwari, S. Shandily, J. Albert, V. Mishra, M. Dikkatwar, R. Singh, S.K. Sah, S. Chand. Insights into medication-induced liver injury: Understanding and management strategies. Toxicology Reports 14 (2025) 101976. https://doi.org/10.1016/J.TOXREP.2025.101976 DOI: https://doi.org/10.1016/j.toxrep.2025.101976

3. J.C.T. Lai, L.Y. Liang, G. Lai-Hung Wong. Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases? Gastroenterology Report 12 (2023) goae096. https://doi.org/10.1093/GASTRO/GOAE024 DOI: https://doi.org/10.1093/gastro/goae024

4. W. Seo, W.I. Jeong. Hepatic non-parenchymal cells: Master regulators of alcoholic liver disease? World Journal of Gastroenterology 22 (2016) 1348-1356. https://doi.org/10.3748/wjg.v22.i4.1348 DOI: https://doi.org/10.3748/wjg.v22.i4.1348

5. J.M. Banales, R.C. Huebert, T. Karlsen, M. Strazzabosco, N.F. LaRusso, G.J. Gores. Cholangiocyte pathobiology. Nature Reviews Gastroenterology and Hepatology 16 (2019) 269-281. https://doi.org/10.1038/s41575-019-0125-y DOI: https://doi.org/10.1038/s41575-019-0125-y

6. J. Behmoaras, K. Mulder, F. Ginhoux, E. Petretto. The spatial and temporal activation of macrophages during fibrosis. Nature Reviews Immunology (2025). https://doi.org/10.1038/s41577-025-01186-x DOI: https://doi.org/10.1038/s41577-025-01186-x

7. Y. Wan, F. Meng, N. Wu, T. Zhou, J. Venter, H. Francis, L. Kennedy, T. Glaser, F. Bernuzzi, P. Invernizzi, S. Glaser, Q. Huang, G. Alpini. Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells. Hepatology 66 (2017) 528-541. https://doi.org/10.1002/hep.29138 DOI: https://doi.org/10.1002/hep.29138

8. N.J. Hunt, P.A.G. McCourt, D.G.Le Couteur, V.C. Cogger. Novel targets for delaying aging: The importance of the liver and advances in drug delivery. Advanced Drug Delivery Reviews 135 (2018) 39-49. https://doi.org/10.1016/j.addr.2018.09.006 DOI: https://doi.org/10.1016/j.addr.2018.09.006

9. J. Gracia-Sancho, E. Caparrós, A. Fernández-Iglesias, R. Francés. Role of liver sinusoidal endothelial cells in liver diseases. Nature Reviews Gastroenterology and Hepatology 18 (2021) 411-431. https://doi.org/10.1038/s41575-020-00411-3 DOI: https://doi.org/10.1038/s41575-020-00411-3

10. Y. Wei, W. Bingyu, Y. Lei, Y. Xingxing. The antifibrotic role of natural killer cells in liver fibrosis. Experimental Biology and Medicine 247 (2022) 1235-1243. https://doi.org/10.1177/15353702221092672 DOI: https://doi.org/10.1177/15353702221092672

11. E. Slevin, L. Baiocchi, N. Wu, B. Ekser, K. Sato, E. Lin, L. Ceci, L. Chen, S.R. Lorenzo, W. Xu, K. Kyritsi, V. Meadows, T. Zhou, D. Kundu, Y. Han, L. Kennedy, S. Glaser, H. Francis, G. Alpini, F. Meng. Kupffer Cells: Inflammation Pathways and Cell-Cell Interactions in Alcohol-Associated Liver Disease. The American Journal of Pathology 190 (2020) 2185-2193. https://doi.org/10.1016/j.ajpath.2020.08.014 DOI: https://doi.org/10.1016/j.ajpath.2020.08.014

12. Y. Wan, W. Zhang, C. Huang, J. Jian, Y. Zhang, Q. Liu, P. Chen, X. Zhu. Ursolic acid alleviates Kupffer cells pyroptosis in liver fibrosis by the NOX2/NLRP3 inflammasome signaling pathway. International Immonopharmacology 113 (2022) 109321. https://doi.org/10.1016/j.intimp.2022.109321 DOI: https://doi.org/10.1016/j.intimp.2022.109321

13. Y. Zhou, D. Long, Y. Zhao, S. Li, Y. Liang, L. Wan, J. Zhang, F. Xue, L. Feng. Oxidative stress-mediated mitochondrial fission promotes hepatic stellate cell activation via stimulating oxidative phosphorylation. Cell Death Disease 13 (2022) 689. https://doi.org/10.1038/s41419-022-05088-x DOI: https://doi.org/10.1038/s41419-022-05088-x

14. J. Plakkal Ayyappan, A. Paul, Y.H. Goo. Lipid droplet-associated proteins in atherosclerosis (Review). Molecular Medicine Reports 13 (2016) 4527-4534. https://doi.org/10.3892/mmr.2016.5099 DOI: https://doi.org/10.3892/mmr.2016.5099

15. T.F. Lee, K.M. Mak, O. Rackovsky, Y.L. Lin, A.J. Kwong, J.C. Loke, S.L. Friedman. Downregulation of hepatic stellate cell activation by retinol and palmitate mediated by adipose differentiation-related protein (ADRP). Journal of Cellular Physiology 223 (2010) 648-657. https://doi.org/10.1002/jcp.22063 DOI: https://doi.org/10.1002/jcp.22063

16. G. Mitropoulou, V. Kompoura, F. Saffioti, V.K. Mavroeidis. The Role of Matrix Metalloproteinases in Liver Function and Disease. Frontiers in Bioscience (Landmark Edition) 30 (2025) 27127. https://doi.org/10.31083/FBL27127 DOI: https://doi.org/10.31083/FBL27127

17. M. Sato, S. Suzuki, H. Senoo. Hepatic stellate cells: Unique characteristics in cell biology and phenotype. Cells Structure and Function 28 (2003) 105-112. https://doi.org/10.1247/csf.28.105 DOI: https://doi.org/10.1247/csf.28.105

18. Q. Tan, D. Xia, X. Ying. miR-29a in Exosomes from Bone Marrow Mesenchymal Stem Cells Inhibit Fibrosis during Endometrial Repair of Intrauterine Adhesion. International Journal of Stem Cells 13 (2020) 414-423. https://doi.org/10.15283/ijsc20049 DOI: https://doi.org/10.15283/ijsc20049

19. R.F. Schwabe, D.A. Brenner. Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease. Nature Reviews Gastroenterology Hepatology 22 (2025) 481-499. https://doi.org/10.1038/s41575-025-01068-6 DOI: https://doi.org/10.1038/s41575-025-01068-6

20. V.Q.H. Trinh, T.F. Lee, S. Lemoinne, K.C. Ray, M.D. Ybanez, T. Tsuchida, J.K. Carter, J. Agudo, B.D. Brown, K.M. Akat, S.L. Friedman, Y.A. Lee. Hepatic stellate cells maintain liver homeostasis through paracrine neurotrophin-3 signaling that induces hepatocyte proliferation. Science Signaling 16 (2023) eadf6696. https://doi.org/10.1126/scisignal.adf6696 DOI: https://doi.org/10.1126/scisignal.adf6696

21. D. Cassiman, C. Denef, V.J. Desmet, T. Roskams. Human and rat hepatic stellate cells express neurotrophins and neurotrophin receptors. Hepatology (Baltimore, Md.) 33 (2001) 148-158. https://doi.org/10.1053/jhep.2001.20793 DOI: https://doi.org/10.1053/jhep.2001.20793

22. Patidar, N. Hirani, S. Bharti, M.S. Baig. Key regulators of hepatic stellate cell activation in alcohol liver Disease: A comprehensive review. International Immunopharmacology 141 (2024) 112938. https://doi.org/10.1016/j.intimp.2024.112938 DOI: https://doi.org/10.1016/j.intimp.2024.112938

23. Y. Geng, R.F. Schwabe. Hepatic stellate cell heterogeneity: Functional aspects and therapeutic implications. Hepatology (2025) 1386. https://doi.org/10.1097/HEP.0000000000001386 DOI: https://doi.org/10.1097/HEP.0000000000001386

24. M.J. McConnell, E. Kostallari, S.H. Ibrahim, Y. Iwakiri. The evolving role of liver sinusoidal endothelial cells in liver health and disease. Hepatology 78 (2023) 649. https://doi.org/10.1097/HEP.0000000000000207 DOI: https://doi.org/10.1097/HEP.0000000000000207

25. J. Poisson, S. Lemoinne, C. Boulanger, F. Durand, R. Moreau, D. Valla, & P.-E. Rautou. Liver sinusoidal endothelial cells: Physiology and role in liver diseases. Journal of Hepatology 66 (2017) 212-227. https://doi.org/10.1016/j.jhep.2016.07.009 DOI: https://doi.org/10.1016/j.jhep.2016.07.009

26. Q. Dai, Q. Ain, N. Seth, H. Zhao, M. Rooney, A. Zipprich. Aging-Associated Liver Sinusoidal Endothelial Cells Dysfunction Aggravates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease. Aging Cell 24 (2025) e14502. https://doi.org/10.1111/acel.14502 DOI: https://doi.org/10.1111/acel.14502

27. B. Gao, S. Radaeva. Natural killer and natural killer T cells in liver fibrosis. Biochimica et Biophysica Acta 1832 (2013) 1061-1069. https://doi.org/10.1016/j.bbadis.2012.09.008 DOI: https://doi.org/10.1016/j.bbadis.2012.09.008

28. P. Ramachandran, J.P. Iredale. Macrophages: Central regulators of hepatic fibrogenesis and fibrosis resolution. Journal of Hepatology 56 (2012) 1417-1419. https://doi.org/10.1016/j.jhep.2011.10.026 DOI: https://doi.org/10.1016/j.jhep.2011.10.026

29. A. Canbay, P. Taimr, N. Torok, H. Higuchi, S. Friedman, G.J. Gores. Apoptotic Body Engulfment by a Human Stellate Cell Line Is Profibrogenic. Laboratory Investigation 83 (2003) 655-663. https://doi.org/10.1097/01.LAB.0000069036.63405.5C DOI: https://doi.org/10.1097/01.LAB.0000069036.63405.5C

30. N. Nieto, S.L. Friedman, A.I. Cederbaum. Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells. The Journal of Biological 277 (2002) 9853-9864. https://doi.org/10.1074/jbc.M110506200 DOI: https://doi.org/10.1074/jbc.M110506200

31. H. Tsukamoto. Epigenetic mechanism of stellate cell trans-differentiation. Journal of Hepatology 46 (2007) 352-353. https://doi.org/10.1016/j.jhep.2006.11.002 DOI: https://doi.org/10.1016/j.jhep.2006.11.002

32. N. Tarrats, A. Moles, A. Morales, C. García-Ruiz, J.C. Fernández-Checa, M. Marí. Critical role of tumor necrosis factor receptor 1, but not 2, in hepatic stellate cell proliferation, extracellular matrix remodeling, and liver fibrogenesis. Hepatology (Baltimore, Md.) 54 (2011) 319-327. https://doi.org/10.1002/hep.24388 DOI: https://doi.org/10.1002/hep.24388

33. L. Chuliá-Peris, C. Carreres-Rey, M. Gabasa, J. Alcaraz, J. Carretero, J. Pereda. Matrix Metallo¬proteinases and Their Inhibitors in Pulmonary Fibrosis: EMMPRIN/CD147 Comes into Play. International Journal of Molecular Sciences 23 (2022) 6894. https://doi.org/10.3390/ijms23136894 DOI: https://doi.org/10.3390/ijms23136894

34. R. Urtasun, A. Lopategi, J. George, T.M. Leung, Y. Lu, X. Wang, X. Ge, M.I. Fiel, N. Nieto. Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin α(V)β(3) engagement and PI3K/pAkt/NFκB signaling. Hepatology (Baltimore, Md.) 55 (2012) 594-608. https://doi.org/10.1002/hep.24701 DOI: https://doi.org/10.1002/hep.24701

35. E. Seki, S.De Minicis, G.Y. Gwak, J. Kluwe, S. Inokuchi, C.A. Bursill, J.M. Llovet, D.A. Brenner, R.F. Schwabe. CCR1 and CCR5 promote hepatic fibrosis in mice. The Journal of Clinical Investigation 119 (2009) 1858-1870. https://doi.org/10.1172/jci37444 DOI: https://doi.org/10.1172/JCI37444

36. D.L. Rebolledo, K.E. Lipson, E. Brandan. Driving fibrosis in neuromuscular diseases: Role and regulation of Connective tissue growth factor (CCN2/CTGF). Matrix Biology Plus 11 (2021) 100059. https://doi.org/10.1016/j.mbplus.2021.100059 DOI: https://doi.org/10.1016/j.mbplus.2021.100059

37. J. Wang, E. S. H. Chu, H.-Y. Chen, K. Man, M. Y. Y. Go, X. R. Huang, H. Y. Lan, J. J. Y. Sung, J. Yu, microRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway. Oncotarget 6 (2015) 7325-7338. https://doi.org/10.18632/oncotarget.2621 DOI: https://doi.org/10.18632/oncotarget.2621

38. E. Novo, D. Povero, C. Busletta, C. Paternostro, L.V. Di Bonzo, S. Cannito, A. Compagnone, A. Bandino, F. Marra, S. Colombatto, E. David, M. Pinzani, M. Parola. The biphasic nature of hypoxia-induced directional migration of activated human hepatic stellate cells. Journal of Pathology 226 (2012) 588-597. https://doi.org/10.1002/path.3005 DOI: https://doi.org/10.1002/path.3005

39. J. Li, S.J. Qiu, W.M. She, F.P. Wang, H. Gao, L. Li, C.T. Tu, J.Y. Wang, X.Z. Shen, W. Jiang. Significance of the balance between regulatory T (Treg) and T helper 17 (Th17) cells during hepatitis B virus related liver fibrosis. Plos One 7(6) (2012) e39307. https://doi.org/10.1371/journal.pone.0039307 DOI: https://doi.org/10.1371/journal.pone.0039307

40. Y. Li, B. Huang, X. Jiang, W. Chen, J. Zhang, Y. Wei, Y. Chen, M. Lian, Z. Bian, Q. Miao, Y. Peng, J. Fang, Q. Wang, R. Tang, M.E. Gershwin, X. Ma. Mucosal-Associated Invariant T Cells Improve Nonalcoholic Fatty Liver Disease Through Regulating Macrophage Polarization. Frontiers in Immunology 9 (2018) 1994. https://doi.org/10.3389/fimmu.2018.01994 DOI: https://doi.org/10.3389/fimmu.2018.01994

41. P. Hegde, E. Weiss, V. Paradis, J. Wan, M. Mabire, S. Sukriti, P.E. Rautou, M. Albuquerque, O. Picq, A.C. Gupta, G. Ferrere, H. Gilgenkrantz, B. Kiaf, A. Toubal, L. Beaudoin, P. Lettéron, R. Moreau, A. Lehuen, S. Lotersztajn. Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver. Nature Communications 9 (2018) 2146. https://doi.org/10.1038/s41467-018-04450-y DOI: https://doi.org/10.1038/s41467-018-04450-y

42. M. Liu, Y. Hu, Y. Yuan, Z. Tian, C. Zhang. γδT Cells Suppress Liver Fibrosis via Strong Cytolysis and Enhanced NK Cell-Mediated Cytotoxicity Against Hepatic Stellate Cells. Frontiers In Immunology 10 (2019) 477. https://doi.org/10.3389/fimmu.2019.00477 DOI: https://doi.org/10.3389/fimmu.2019.00477

43. W. Seo, H.S. Eun, S.Y. Kim, H.S. Yi, Y.S. Lee, S.H. Park, M.J. Jang, E. Jo, S.C. Kim, Y.M. Han, K.G. Park, W.I. Jeong. Exosome-mediated activation of toll-like receptor 3 in stellate cells stimulates interleukin-17 production by γδ T cells in liver fibrosis. Hepatology (Baltimore, Md.) 64 (2016) 616-631. https://doi.org/10.1002/hep.28644 DOI: https://doi.org/10.1002/hep.28644

44. H. Gilgenkrantz, R.A. Sayegh, S. Lotersztajn. Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy. Annual Review of Pharmacology and Toxicology 65 (2025) 281-299. https://doi.org/10.1146/annurev-pharmtox-020524-012013 DOI: https://doi.org/10.1146/annurev-pharmtox-020524-012013

45. R.S. Wijaya, S.A. Read, S. Schibeci, M. Eslam, M.K. Azardaryany, K. El-Khobar, D. van der Poorten, R. Lin, L. Yuen, V. Lam, J. George, M.W. Douglas, G. Ahlenstiel. KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B. Journal of Hepatology 71 (2019) 252-264. https://doi.org/10.1016/j.jhep.2019.03.012 DOI: https://doi.org/10.1016/j.jhep.2019.03.012

46. A. Sugimoto, Y. Saito, G. Wang, Q. Sun, C. Yin, K.H. Lee, Y. Geng, P. Rajbhandari, C. Hernan-dez, M. Steffani, J. Qie, T. Savage, D.M. Goyal, K.C. Ray, T.V. Neelakantan, D. Yin, J. Melms, B.M. Lehrich, T.M. Yasaka, S. Liu, M. Oertel, T. Lan, A. Guillot, M. Peiseler, A. Filliol, H. Kan-zaki, N. Fujiwara, S. Ravi, B. Izar, M. Brosch, J. Hampe, H. Remotti, J. Argemi, Z. Sun, T.J. Kendall, Y. Hoshida, F. Tacke, J.A. Fallowfield, S.K. Blockley-Powell, R.A. Haeusler, J.B. Stein-man, U.B. Pajvani, S.P. Monga, R. Bataller, M. Masoodi, N. Arpaia, Y.A. Lee, B.R. Stockwell, H.G. Augustin, R.F. Schwabe. Hepatic stellate cells control liver zonation, size and functions via R-spondin 3. Nature 640 (2025) 752-761. https://doi.org/10.1038/s41586-025-08677-w DOI: https://doi.org/10.1038/s41586-025-08677-w

47. V. Merens, E. Knetemann, E. Gürbüz, V. De Smet, N. Messaoudi, H. Reynaert, S. Verhulst, L. A. van Grunsven. Hepatic stellate cell single cell atlas reveals a highly similar activation process across liver disease aetiologies. JHEP Reports 7 (2025) 101223. https://doi.org/10.1016/J.JHEPR.2024.101223 DOI: https://doi.org/10.1016/j.jhepr.2024.101223

48. X. Jiang, W. Zhao, B. Shen, Y. Han, K. Chen. CD47-mediated regulation of glucose and lipid metabolism: implications for the pathogenesis of MASLD. Frontiers In Endocrinology 16 (2025). https://doi.org/10.3389/fendo.2025.1535382 DOI: https://doi.org/10.3389/fendo.2025.1535382

49. D.W. Zhang, Y.X. Zhao, D. Wei, Y.L. Li, Y. Zhang, J. Wu, J. Xu, C. Chen, H. Tang, W. Zhang, L. Gong, Y. Han, Z.N. Chen, H. Bian. HAb18G/CD147 promotes activation of hepatic stellate cells and is a target for antibody therapy of liver fibrosis. Journal of Hepatology 57 (2012) 1283-1291. https://doi.org/10.1016/J.JHEP.2012.07.042 DOI: https://doi.org/10.1016/j.jhep.2012.07.042

50. L. Pirola. Elafibranor, a dual PPARα and PPARδ agonist, reduces alcohol-associated liver disease: Lessons from a mouse model. World Journal of Gastroenterology 31 (2025) 99312. https://doi.org/10.3748/wjg.v31.i4.99312 DOI: https://doi.org/10.3748/wjg.v31.i4.99312

51. G. Huang, M. Zhang, M. Wang, W. Xu, X. Duan, X. Han, J. Ren, Pioglitazone. a peroxisome proliferator activated receptor γ agonist, induces cell death and inhibits the proliferation of hypoxic HepG2 cells by promoting excessive production of reactive oxygen species. Oncology Letters 27 (2024) 160. https://doi.org/10.3892/ol.2024.14294 DOI: https://doi.org/10.3892/ol.2024.14294

52. S. Fiorucci, M. Biagioli, M. Baldoni, P. Ricci, V. Sepe, A. Zampella, E. Distrutti. The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease. Expert Opinion on Drug Discovery 16 (2021) 1193-1208. https://doi.org/10.1080/17460441.2021.1916465 DOI: https://doi.org/10.1080/17460441.2021.1916465

53. V. Lekakis, E. Cholongitas. The impact of emricasan on chronic liver diseases: current data. Clinical Journal of Gastroenterology 15 (2022) 271-285. https://doi.org/10.1007/s12328-021-01585-2 DOI: https://doi.org/10.1007/s12328-021-01585-2

54. S.A. Harrison, P. Bedossa, C.D. Guy, J.M. Schattenberg, R. Loomba, R. Taub, D. Labriola, S.E. Moussa, G.W. Neff, M.E. Rinella, Q.M. Anstee, M.F. Abdelmalek, Z. Younossi, S.J. Baum, S. Francque, M.R. Charlton, P.N. Newsome, N. Lanthier, I. Schiefke, A. Mangia, J.M. Pericàs, R. Patil, A.J. Sanyal, M. Noureddin, M.B. Bansal, N. Alkhouri, L. Castera, M. Rudraraju, V. Ratziu. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. New England Journal of Medicine 390 (2024) 497-509. https://doi.org/10.1056/NEJMOA2309000 DOI: https://doi.org/10.1056/NEJMoa2309000

55. X. Xu, Y. Guo, X. Luo, Z. Shen, Z. Sun, B. Shen, C. Zhou, J. Wang, J. Lu, Q. Zhang, Y. Ye, Y. Luo, Y. Qu, X. Cai, H. Dong, L. Lu. Hydronidone ameliorates liver fibrosis by inhibiting activation of hepatic stellate cells via Smad7-mediated degradation of TGFβRI. Liver International 43 (2023) 2523-2537. https://doi.org/10.1111/LIV.15715 DOI: https://doi.org/10.1111/liv.15715

56. N. Chalasani, M.F. Abdelmalek, G. Garcia-Tsao, R. Vuppalanchi, N. Alkhouri, M. Rinella, M. Noureddin, M. Pyko, M. Shiffman, A. Sanyal, A. Allgood, H. Shlevin, R. Horton, E. Zomer, W. Irish, Z. Goodman, S.A. Harrison, P.G. Traber, L. Balart, B. Borg, M. Charlton, H. Conjeevaram, M. Fuchs, R. Ghalib, P. Gholam, D. Halegoua-De Marzio, S. Harrison, C. Jue, N. Kemmer, K. Kowdley, M. Lai, E. Lawitz, R. Loomba, A. Paredes, D. Rockey, M. Rodriguez, R. Rubin, M. Ryan, A. Scanga, T. Sepe, B. Tetri, P. Thuluvath, D. Torres, J. Vierling, J. Wattacheril, A. Weiland, D. Zogg. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis with Cirrhosis and Portal Hypertension. Gastroenterology 158 (2020) 1334-1345.e5. https://doi.org/10.1053/J.GASTRO.2019.11.296 DOI: https://doi.org/10.1053/j.gastro.2019.11.296

57. S. Petta, G. Targher, S. Romeo, U.B. Pajvani, M.H. Zheng, A. Aghemo, L.V.C. Valenti. The first MASH drug therapy on the horizon: Current perspectives of resmetirom. Liver International 44 (2024) 1526-1536. https://doi.org/10.1111/LIV.15930 DOI: https://doi.org/10.1111/liv.15930

58. M. Kram. Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis. World Journal of Hepatology 15 (2023) 201-207. https://doi.org/10.4254/wjh.v15.i2.201 DOI: https://doi.org/10.4254/wjh.v15.i2.201

59. S.A. Nasir, A. Mangla, V. Taneja, T. Berger, D. Pandya, V. Gupta, J.K. Lim. Advances in Novel Drug Therapy for Metabolic Dysfunction-associated Steatohepatitis Cirrhosis. Journal of Translational Gastroenterology 3 (2025) 9-17. https://doi.org/10.14218/JTG.2024.00040 DOI: https://doi.org/10.14218/JTG.2024.00040

60. D. Ezhilarasan. Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD. Metabolism 155 (2024) 155912. https://doi.org/10.1016/j.metabol.2024.155912 DOI: https://doi.org/10.1016/j.metabol.2024.155912

61. C.M. Hayes, G.M. Gallucci, J.L. Boyer, D.N. Assis, N.S. Ghonem. PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress. Hepatology Communications 9 (2024). https://doi.org/10.1097/HC9.0000000000000612 DOI: https://doi.org/10.1097/HC9.0000000000000612

62. S.J. Keam. Resmetirom: First Approval. Drugs 84 (2024) 729-735. https://doi.org/10.1007/s40265-024-02045-0 DOI: https://doi.org/10.1007/s40265-024-02045-0

63. J.M. Yabut, D.J. Drucker. Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease. Endocrine Reviews 44 (2023) 14-32. https://doi.org/10.1210/endrev/bnac018 DOI: https://doi.org/10.1210/endrev/bnac018

64. A.J. Sanyal, P.N. Newsome, I. Kliers, L.H. Østergaard, M.T. Long, M.S. Kjær, A.M.G. Cali, E. Bugianesi, M.E. Rinella, M. Roden, V. Ratziu. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. New England Journal of Medicine 392 (2025) 2089-2099. https://doi.org/10.1056/NEJMOA2413258 DOI: https://doi.org/10.1056/NEJMoa2413258

65. A. Azizsoltani, B. Niknam, M. Taghizadeh-Teymorloei, E. Ghoodjani, H. Dianat-Moghadam, E. Alizadeh. Therapeutic implications of obeticholic acid, a farnesoid X receptor agonist, in the treatment of liver fibrosis. Biomedicine Pharmacotherapy 189 (2025) 11829. https://doi.org/10.1016/j.biopha.2025.118249 DOI: https://doi.org/10.1016/j.biopha.2025.118249

66. V.J. Thannickal, K. Jandeleit-Dahm, C. Szyndralewiez, N.J. Török. Pre-clinical evidence of a dual NADPH oxidase 1/4 inhibitor (setanaxib) in liver, kidney and lung fibrosis. Journal of Cellular and Molecular Medicine 27 (2023) 471-481. https://doi.org/10.1111/jcmm.17649 DOI: https://doi.org/10.1111/jcmm.17649

67. S.M. El Haggar, S.K. Hegazy, S.M. Abd-Elsalam, M.M. Bahaa. Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine. Biomedicine Pharmacotherapy 145 (2022) 112399. https://doi.org/10.1016/j.biopha.2021.112399 DOI: https://doi.org/10.1016/j.biopha.2021.112399

68. X. Cai, X. Liu, W. Xie, A. Ma, Y. Tan, J. Shang, J. Zhang, C. Chen, Y. Yu, Y. Qu, L. Zhang, Y. Luo, P. Yin, J. Cheng, L. Lu. Hydronidone for the Treatment of Liver Fibrosis Related to Chronic Hepatitis B: A Phase 2 Randomized Controlled Trial. Clinical Gastroenterology and Hepatology 21 (2023) 1893-1901.e7. https://doi.org/10.1016/j.cgh.2022.05.056 DOI: https://doi.org/10.1016/j.cgh.2022.05.056

69. J. Zhang, Q. Wang, N. Zhou, J. Liu, L. Tao, Z. Peng, G. Hu, H. Wang, L. Fu, S. Peng. Fluorofenidone attenuates choline-deficient, l-amino acid-defined, high-fat diet-induced metabolic dysfunction-associated steatohepatitis in mice. Scientific Reports 15 (2025) 9863. https://doi.org/10.1038/s41598-025-94401-7 DOI: https://doi.org/10.1038/s41598-025-94401-7

70. Z. Ma, K. Jin, M. Yue, X. Chen, J. Chen. Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes. Journal of Diabetes Research 2023 (2023) 5891532. https://doi.org/10.1155/2023/5891532 DOI: https://doi.org/10.1155/2023/5891532

71. N. Alkhouri, E. Lawitz, M. Noureddin, R. DeFronzo, G.I. Shulman. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). Expert Opinion on Investigational Drugs 29 (2020) 135-141. https://doi.org/10.1080/13543784.2020.1668374 DOI: https://doi.org/10.1080/13543784.2020.1668374

72. R. Loomba, A.J. Sanyal, A. Nakajima, B.A. Neuschwander-Tetri, Z.D. Goodman, S.A. Harrison, E.J. Lawitz, N. Gunn, K. Imajo, N. Ravendhran, T. Akahane, B. Boone, M. Yamaguchi, A. Chatterjee, G.S. Tirucherai, D.E. Shevell, S. Du, E.D. Charles, M.F. Abdelmalek. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study. Clinical Gastroenterology and Hepatology 22 (2024) 102-112.e9. https://doi.org/10.1016/j.cgh.2023.04.011 DOI: https://doi.org/10.1016/j.cgh.2023.04.011

73. M.E. Rinella, H.D. Lieu, K.V. Kowdley, Z.D. Goodman, N. Alkhouri, E. Lawitz, V. Ratziu, M.F. Abdelmalek, V.W.S. Wong, Z.H. Younes, A.M. Sheikh, D. Brannan, B. Freilich, F. Membreno, M. Sinclair, L. Melchor-Khan, A.J. Sanyal, L. Ling, S.A. Harrison. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology 79 (2024) 674-689. https://doi.org/10.1097/HEP.0000000000000607 DOI: https://doi.org/10.1097/HEP.0000000000000607

74. V. Ratziu, Y. Yilmaz, D. Lazas, S.L. Friedman, C. Lackner, C. Behling, O.W. Cummings, L. Chen, M. Petitjean, Y. Gilgun-Sherki, T. Gorfine, S. Kadosh, E. Eyal, A.J. Sanyal. Aramchol improves hepatic fibrosis in metabolic dysfunction-associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology. Hepatology 81 (2025) 932. https://doi.org/10.1097/HEP.0000000000000980 DOI: https://doi.org/10.1097/HEP.0000000000000980

75. F. Ciftci, A.C. Özarslan, İ.C. Kantarci, A. Yelkenci, O. Tavukcuoglu, M. Ghorbanpour. Advances in Drug Targeting, Drug Delivery, and Nanotechnology Applications: Therapeutic Significance in Cancer Treatment. Pharmaceutics 17 (2025) 121. https://doi.org/10.3390/pharmaceutics17010121 DOI: https://doi.org/10.3390/pharmaceutics17010121

76. X. Han, Z.Y. Cui, J. Song, H.Q. Piao, L.H. Lian, L.S. Hou, G. Wang, S. Zheng, X.X. Dong, J.X. Nan, Y.L. Wu. Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner. Chemico-Biological Interactions 311 (2019) 108794. https://doi.org/10.1016/j.cbi.2019.108794 DOI: https://doi.org/10.1016/j.cbi.2019.108794

77. A. Azizsoltani, B. Hatami, M.R. Zali, V. Mahdavi, K. Baghaei, E. Alizadeh. Obeticholic acid-loaded exosomes attenuate liver fibrosis through dual targeting of the FXR signaling pathway and ECM remodeling. Biomedicine Pharmacotherapy 168 (2023) 115777. https://doi.org/10.1016/j.biopha.2023.115777 DOI: https://doi.org/10.1016/j.biopha.2023.115777

78. S. Girisa, B.S. Aswani, M.K. Manickasamy, M. Hegde, M.S. Alqahtani, M. Abbas, G. Sethi, A.B. Kunnumakkara. Restoring FXR expression as a novel treatment strategy in liver cancer and other liver disorders. Expert Opinion on Therapeutic Targets 29 (2025) 193-221. https://doi.org/10.1080/14728222.2025.2487465 DOI: https://doi.org/10.1080/14728222.2025.2487465

79. N.S. El-Mezayen, W.F. El-Hadidy, W.M. El-Refaie, T.I. Shalaby, M.M. Khattab, A.S. El-Khatib. Oral vitamin-A-coupled valsartan nanomedicine: High hepatic stellate cell receptors accessibility and prolonged enterohepatic residence. Journal of Controlled Release 283 (2018) 32-44. https://doi.org/10.1016/j.jconrel.2018.05.021 DOI: https://doi.org/10.1016/j.jconrel.2018.05.021

80. Y.W. Zhang, L.S. Hou, J.H. Xing, T.R. Zhang, S.Y. Zhou, B.L. Zhang. Two-Membrane Hybrid Nanobiomimetic Delivery System for Targeted Autophagy Inhibition of Activated Hepatic Stellate Cells To Synergistically Treat Liver Fibrosis. ACS Applied Materials Interfaces 15 (2023) 50863-50877. https://doi.org/10.1021/acsami.3c11046 DOI: https://doi.org/10.1021/acsami.3c11046

81. S. Tan, H. Liu, B. Ke, J. Jiang, B. Wu. The peripheral CB receptor antagonist JD5037 attenuates liver fibrosis via a CB receptor/β-arrestin1/Akt pathway. British Journal of Pharmacology 177 (2020) 2830-2847. https://doi.org/10.1111/bph.15010 DOI: https://doi.org/10.1111/bph.15010

82. A.M. Ali, O.S. El-Tawil, A.K. Al-Mokaddem, S.S. Abd El-Rahman. Promoted inhibition of TLR4/miR-155/ NFkB p65 signaling by cannabinoid receptor 2 agonist (AM1241), aborts inflammation and progress of hepatic fibrosis induced by thioacetamide. Chemo-Biological Interactions 336 (2021) 109398. https://doi.org/10.1016/j.cbi.2021.109398 DOI: https://doi.org/10.1016/j.cbi.2021.109398

83. B. Li, C. Yan, J. Wu, K. Stephane, X. Dong, Y.Z. Zhang, Y. Zhang, Q. Yu, K.Y. Zheng. Clonorchis sinensis ESPs enhance the activation of hepatic stellate cells by a cross-talk of TLR4 and TGF-β/Smads signaling pathway. Acta Tropica 205 (2020) 105307. https://doi.org/10.1016/j.actatropica.2019.105307 DOI: https://doi.org/10.1016/j.actatropica.2019.105307

84. B.L. Sun, X. Sun, C.L. Kempf, J.H. Song, N.G. Casanova, S.M. Camp, V. Reyes Hernon, M. Fallon, C. Bime, D.R. Martin, C. Travelli, D.D. Zhang, J.G.N. Garcia. Involvement of eNAMPT/TLR4 inflammatory signaling in progression of non-alcoholic fatty liver disease, steatohepatitis, and fibrosis. The FASEB Journal 37 (2023) e22825. https://doi.org/10.1096/fj.202201972RR DOI: https://doi.org/10.1096/fj.202201972RR

85. M. Zhang, E. Barroso, L. Peña, P. Rada, Á.M. Valverde, W. Wahli, X. Palomer, M. Vázquez-Carrera. PPARβ/δ attenuates hepatic fibrosis by reducing SMAD3 phosphorylation and p300 levels via AMPK in hepatic stellate cells. Biomedicine and Pharmacotherapy 179 (2024) 117303. https://doi.org/10.1016/j.biopha.2024.117303 DOI: https://doi.org/10.1016/j.biopha.2024.117303

86. A.N. Moon, F. Briand, N. Breyner, D.K. Song, M.R. Madsen, H. Kim, K. Choi, Y. Lee, W. Namkung. Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist. Biomedicine Pharmacotherapy 173 (2024) 116331. https://doi.org/10.1016/j.biopha.2024.116331 DOI: https://doi.org/10.1016/j.biopha.2024.116331

87. H.M. Liu, T.Y. Lee, J.F. Liao. GW4064 attenuates lipopolysaccharide-induced hepatic inflammation and apoptosis through inhibition of the Toll-like receptor 4-mediated p38 mitogen-activated protein kinase signaling pathway in mice. International Journal of Molecular Medicine 41 (2018) 1455-1462. https://doi.org/10.3892/ijmm.2018.3366 DOI: https://doi.org/10.3892/ijmm.2018.3366

88. L.G. Di Pasqua, M. Cagna, G. Palladini, A.C. Croce, M. Cadamuro, L. Fabris, S. Perlini, L. Adorini, A. Ferrigno, M. Vairetti. FXR agonists INT-787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet-induced ob/ob mouse model of NASH. Liver International 44 (2024) 214-227. https://doi.org/10.1111/liv.15767 DOI: https://doi.org/10.1111/liv.15767

89. B. Anfuso, C. Tiribelli, L. Adorini, N. Rosso. Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model. Scientific Reports 10 (2020) 1699. https://doi.org/10.1038/s41598-020-58562-x DOI: https://doi.org/10.1038/s41598-020-58562-x

90. S. Feng, X. Xie, J. Li, X. Xu, C. Chen, G. Zou, G. Lin, T. Huang, R. Hu, T. Ran, L. Han, Q. Zhang, Y. Li, X. Zhao. Bile acids induce liver fibrosis through the NLRP3 inflammasome pathway and the mechanism of FXR inhibition of NLRP3 activation. Hepatology International 18 (2024) 1040-1052. https://doi.org/10.1007/s12072-023-10610-0 DOI: https://doi.org/10.1007/s12072-023-10610-0

91. Y. Jiang, L. Hou, J. Dou, M. Xuan, Z. Cui, L. Lian, J. Nan, Y. Wu. Sesamol as a potential candidate for the treatment of hepatic fibrosis, based on its regulation of FXR/LXR axis-mediated inhibition of autophagy through crosstalk between hepatic cells and macrophage. Phytomedicine 123 (2024) 155145. https://doi.org/10.1016/j.phymed.2023.155145 DOI: https://doi.org/10.1016/j.phymed.2023.155145

92. M. Sengupta, K. Griffett, C.A. Flaveny, T.P. Burris. Inhibition of Hepatotoxicity by a LXR Inverse Agonist in a Model of Alcoholic Liver Disease. ACS Pharmacology Translational Science 1 (2018) 50-60. https://doi.org/10.1021/acsptsci.8b00003 DOI: https://doi.org/10.1021/acsptsci.8b00003

93. K. Griffett, T.P. Burris. Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease. Biochemical and Biophysical Research Communications 479 (2016) 424-428. https://doi.org/10.1016/j.bbrc.2016.09.036 DOI: https://doi.org/10.1016/j.bbrc.2016.09.036

94. F. Zhang, S. Lu, J. He, H. Jin, F. Wang, L. Wu, J. Shao, A. Chen, S. Zheng. Ligand Activation of PPARγ by Ligustrazine Suppresses Pericyte Functions of Hepatic Stellate Cells via SMRT-Mediated Transrepression of HIF-1α. Theranostics 8 (2018) 610-626. https://doi.org/10.7150/thno.22237 DOI: https://doi.org/10.7150/thno.22237

95. B.de Souza Basso, G.V. Haute, M. Ortega-Ribera, C. Luft, G.L. Antunes, M.S. Bastos, L.P. Carlessi, V.G. Levorse, E. Cassel, M.V. Fagundes Donadio, E.R. Santarém, J. Gracia-Sancho, J. Rodrigues de Oliveira. Methoxyeugenol deactivates hepatic stellate cells and attenuates liver fibrosis and inflammation through a PPAR-ɣ and NF-kB mechanism. Journal of Ethnopharmacology 280 (2021) 114433. https://doi.org/10.1016/j.jep.2021.114433 DOI: https://doi.org/10.1016/j.jep.2021.114433

96. L. Chen, L. Li, J. Chen, L. Li, Z. Zheng, J. Ren, Y. Qiu. Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells. Oncotarget 6 (2015) 42530-42540. https://doi.org/10.18632/oncotarget.6466 DOI: https://doi.org/10.18632/oncotarget.6466

97. A. Sandoval-Rodriguez, H.C. Monroy-Ramirez, A. Meza-Rios, J. Garcia-Bañuelos, J. Vera-Cruz, J. Gutiérrez-Cuevas, J. Silva-Gomez, B. Staels, J. Dominguez-Rosales, M. Galicia-Moreno, M. Vazquez-Del Mercado, J. Navarro-Partida, A. Santos-Garcia, J. Armendariz-Borunda. Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK. Hepatology Communications 4 (2020) 434-449. https://doi.org/10.1002/hep4.1474 DOI: https://doi.org/10.1002/hep4.1474

98. Z. Zhou, L. Deng, L. Hu, Q. Ren, Z. Cai, B. Wang, Z. Li, L. Zhang. Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor α/δ agonist, in rodent model of nonalcoholic steatohepatitis. European Journal of Pharmacology 882 (2020) 173300. https://doi.org/10.1016/j.ejphar.2020.173300 DOI: https://doi.org/10.1016/j.ejphar.2020.173300

99. A. Honda, S. Kamata, C. Satta, Y. Machida, K. Uchii, K. Terasawa, A. Nemoto, T. Oyama, I. Ishii. Structural basis for anti-non-alcoholic fatty liver disease and diabetic dyslipidemia drug saroglitazar as a PPAR α/γ dual agonist. Biological and Pharmaceutical Bulletin 44 (2021) 1210. https://doi.org/10.1248/bpb.b21-00232 DOI: https://doi.org/10.1248/bpb.b21-00232

100. M. Kumazoe, E. Miyamoto, C. Oka, M. Kondo, R. Yoshitomi, H. Onda, Y. Shimada, Y. Fujimura, H. Tachibana. miR-12135 ameliorates liver fibrosis accompanied with the downregulation of integrin subunit alpha 11. IsciencE 27 (2024) 108730. https://doi.org/10.1016/j.isci.2023.108730 DOI: https://doi.org/10.1016/j.isci.2023.108730

101. D. Reichert, L. Adolph, J.P. Köhler, T. Buschmann, T. Luedde, D. Häussinger, C. Kordes. Improved recovery from liver fibrosis by crenolanib. Cells 10 (2021) 804. https://doi.org/10.3390/cells10040804 DOI: https://doi.org/10.3390/cells10040804

102. F. Liu, S. Li, P. Chen, Y. Gu, S. Wang, L. Wang, C. Chen, R. Wang, Y. Yuan. Salvianolic acid B inhibits hepatic stellate cell activation and liver fibrosis by targeting PDGFRβ. International Immunopharmacology 122 (2023) 110550. https://doi.org/10.1016/j.intimp.2023.110550 DOI: https://doi.org/10.1016/j.intimp.2023.110550

103. S. Mekala, G. Sukumar, S. Chawla, R. Geesala, J. Prashanth, B.J.M. Reddy, P. Mainkar, A. Das. Therapeutic Potential of Benzimidazoisoquinoline Derivatives in Alleviating Murine Hepatic Fibrosis. Chemistry Biodiversity 21 (2024) e202301429. https://doi.org/10.1002/cbdv.202301429 DOI: https://doi.org/10.1002/cbdv.202301429

104. R. Wang, F. Liu, P. Chen, S. Li, Y. Gu, L. Wang, C. Chen, Y. Yuan. Gomisin D alleviates liver fibrosis through targeting PDGFRβ in hepatic stellate cells. International Journal of Biological Macromolecules 235 (2023) 123639. https://doi.org/10.1016/j.ijbiomac.2023.123639 DOI: https://doi.org/10.1016/j.ijbiomac.2023.123639

105. Z. Chen, H. Liu, A. Jain, L. Zhang, C. Liu, K. Cheng. Discovery of aptamer ligands for hepatic stellate cells using SELEX. Theranostics 7 (2017) 2982-2995. https://doi.org/10.7150/thno.19374 DOI: https://doi.org/10.7150/thno.19374

106. A. Mohamed, O. El-Tawil, S. El-Rahman. Inhibited TLR-4/NF- κB Pathway Mediated by Cannabinoid Receptor 2 Activation Curbs Ongoing Liver Fibrosis in Bile Duct Ligated Rats. Advances in Animal and Veterinary Sciences 9 (2020) 253-264. https://doi.org/10.17582/journal.aavs/2021/9.2.253.264 DOI: https://doi.org/10.17582/journal.aavs/2021/9.2.253.264

107. N. Aljobaily, K. Krutsinger, M.J. Viereckl, R. Joly, B. Menlove, B. Cone, A. Suppes, Y. Han. Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor. Nutrients 15(1) (2023) 178. https://doi.org/10.3390/nu15010178 DOI: https://doi.org/10.3390/nu15010178

108. V.De Nunzio, L. Carrieri, M.P. Scavo, T. Lippolis, M. Cofano, G.R. Caponio, V. Tutino, F. Rizzi, N. Depalo, A.R. Osella, M. Notarnicola. Plasma-Derived Exosomes from NAFLD Patients Modulate the Cannabinoid Receptors’ Expression in Cultured HepaRG Cells. International Journal of Molecular Sciences 24(2) (2023) 1739. https://doi.org/10.3390/ijms24021739 DOI: https://doi.org/10.3390/ijms24021739

109. L.S. Hou, Z.Y. Cui, P. Sun, H.Q. Piao, X. Han, J. Song, G. Wang, S. Zheng, X.X. Dong, L. Gao, Y. Zhu, L.H. Lian, J.X. Nan, Y.L. Wu. Rutin mitigates hepatic fibrogenesis and inflammation through targeting TLR4 and P2X7 receptor signaling pathway in vitro and in vivo. Journal of Functional Foods 64 (2020) 103700. https://doi.org/10.1016/j.jff.2019.103700 DOI: https://doi.org/10.1016/j.jff.2019.103700

110. B.X. Tang, Y. Zhang, D.D. Sun, Q.Y. Liu, C. Li, P.P. Wang, L.X. Gao, X.M. Zhang, J. Li, W.L. Zhu, Y. Zang. Luteolin-7-diglucuronide, a novel PTP1B inhibitor, ameliorates hepatic stellate cell activation and liver fibrosis in mice. Acta Pharmacologica Sinica 46 (2024) 122-133. https://doi.org/10.1038/S41401-024-01351-3 DOI: https://doi.org/10.1038/s41401-024-01351-3

111. N.M. El-Sayed, E.T. Menze, M.G. Tadros, D.M.F. Hanna. Mangiferin mitigates methotrexate-induced liver injury and suppresses hepatic stellate cells activation in rats: Imperative role of Nrf2/NF-κB/NLRP3 signaling axis. Journal of Ethnopharmacology 340 (2025) 119296. https://doi.org/10.1016/J.JEP.2024.119296 DOI: https://doi.org/10.1016/j.jep.2024.119296

112. L. Gan, Q. Jiang, D. Huang, X. Wu, X. Zhu, L. Wang, W. Xie, J. Huang, R. Fan, Y. Jing, G. Tang, X. D. Li, J. Guo, S. Yin. A natural small molecule alleviates liver fibrosis by targeting apolipoprotein L2. Nature Chemical Biology 21 (2024) 80-90. https://doi.org/10.1038/s41589-024-01704-3 DOI: https://doi.org/10.1038/s41589-024-01704-3

113. L. Huang, Y. Chen, X. Fan, X. Zhang, X. Wang, L. Liu, T. Liu, P. Wang, A. Xu, X. Zhao, M. Cong. Fluorofenidone mitigates liver fibrosis through GSK-3β modulation and hepatocyte protection in a 3D tissue-engineered model. International Immunopharmacology 149 (2025) 114209. https://doi.org/10.1016/J.INTIMP.2025.114209 DOI: https://doi.org/10.1016/j.intimp.2025.114209

114. M. Lv, S. Chen, M. Shan, Y. Si, C. Huang, J. Chen, L. Gong. Arctigenin induces activated HSCs quiescence via AMPK-PPARγ pathway to ameliorate liver fibrosis in mice. European Journal of Pharmacology 974 (2024) 176629. https://doi.org/10.1016/J.EJPHAR.2024.176629 DOI: https://doi.org/10.1016/j.ejphar.2024.176629

115. M.ten Hove, A. Smyris, R. Booijink, L. Wachsmuth, U. Hansen, L. Alic, C. Faber, C. Hӧltke, R. Bansal. Engineered SPIONs functionalized with endothelin a receptor antagonist ameliorate liver fibrosis by inhibiting hepatic stellate cell activation. Bioactive Materials 39 (2024) 406-426. https://doi.org/10.1016/j.bioactmat.2024.05.034 DOI: https://doi.org/10.1016/j.bioactmat.2024.05.034

116. M. Yuan, Z. Yin, Z. Wang, Z. Xiong, P. Chen, L. Yao, P. Liu, M. Sun, K. Shu, L. Li, Y. Jiang. Modifi¬cation of MSCs with aHSCs-targeting peptide pPB for enhanced therapeutic efficacy in liver fibrosis. Biomaterials 321 (2025) 123295. https://doi.org/10.1016/J.BIOMATERIALS.2025.123295 DOI: https://doi.org/10.1016/j.biomaterials.2025.123295

117. P. Yang, W. Liu, Z. Chen, D. Duan, J. Xu, X. An, A. Xie, Z. Rao, Y. Xia, R. Zhang, P. Ning, C. Qiao, X. Zhang, Z. Wang. Sono-mediated glutamine metabolic nanoplatform against liver fibrosis via breaking the vicious self-injury of activated hepatic stellate cells. Nano Today 61 (2025) 102641. https://doi.org/10.1016/J.NANTOD.2025.102641 DOI: https://doi.org/10.1016/j.nantod.2025.102641

118. Y. Xu, Y. Fan, Z. Zhao, W. Hu, Y. Qian, Y. Hu. Circularized Supramolecular Spherical Nucleic Acids Alleviates Liver Fibrosis through Blocking Upstream Activation and Reversing Activation State of Hepatic Stellate Cells. ACS Nano 19(16) (2025) 15444-15456. https://doi.org/10.1021/ACSNANO.4C15562 DOI: https://doi.org/10.1021/acsnano.4c15562

119. J. Huang, H. Huang, Y. Wang, B. Xu, M. Lin, S. Han, Y. Yuan, Y. Wang, X. Shuai. Retinol-binding protein-hijacking nanopolyplex delivering siRNA to cytoplasm of hepatic stellate cell for liver fibrosis alleviation. Biomaterials 299 (2023) 122134. https://doi.org/10.1016/j.biomaterials.2023.122134 DOI: https://doi.org/10.1016/j.biomaterials.2023.122134

120. M. Azzam, S. El Safy, S.A. Abdelgelil, R. Weiskirchen, A. Asimakopoulou, F. de Lorenzi, T. Lammers, S. Mansour, S. Tammam. Targeting Activated Hepatic Stellate Cells Using Collagen-Binding Chitosan Nanoparticles for siRNA Delivery to Fibrotic Livers. Pharmaceutics 12(6) (2020) 590. https://doi.org/10.3390/pharmaceutics12060590 DOI: https://doi.org/10.3390/pharmaceutics12060590

121. M.A. Younis, Y. Sato, Y.H.A. Elewa, H. Harashima. Reprogramming activated hepatic stellate cells by siRNA-loaded nanocarriers reverses liver fibrosis in mice. Journal of Controlled Release 361 (2023) 592-603. https://doi.org/10.1016/j.jconrel.2023.08.021 DOI: https://doi.org/10.1016/j.jconrel.2023.08.021

122. M.X. Liu, L. Xu, Y.T. Cai, R.J. Wang, Y.Y. Gu, Y.C. Liu, Y.J. Zou, Y.M. Zhao, J. Chen, X.L. Zhang. Carbon Nitride-Based siRNA Vectors with Self-Produced O(2) Effects for Targeting Combination Therapy of Liver Fibrosis via HIF-1α-Mediated TGF-β1/Smad Pathway. Advanced Healthcare Materials 12 (2023) e2301485. https://doi.org/10.1002/adhm.202301485 DOI: https://doi.org/10.1002/adhm.202301485

123. L. Wang, J. Zhou, J. Wang, X. Wang, H. Dong, L. Zhao, J. Wu, J. Peng. Hepatic Stellate Cell-Targeting Micelle Nanomedicine for Early Diagnosis and Treatment of Liver Fibrosis. Advanced Healthcare Materials 13(12) (2024) 2303710. https://doi.org/10.1002/adhm.202303710 DOI: https://doi.org/10.1002/adhm.202303710

124. Y.N. Chen, S.L. Hsu, M.Y. Liao, Y.T. Liu, C.H. Lai, J.F. Chen, M.H.T. Nguyen, Y.H.Su, S.T. Chen, L.C. Wu. Ameliorative effect of curcumin-encapsulated hyaluronic acid-PLA nanoparticles on thioacetamide-induced murine hepatic fibrosis. International Journal of Environmental Research and Public Health 14(1) (2017) 11. https://doi.org/10.3390/ijerph14010011 DOI: https://doi.org/10.3390/ijerph14010011

125. Y. Liu, S. Chen, H. Huang, A.C. Midgley, Z. Han, Z.C. Han, Q. Li, Z. Li. Ligand-Tethered Extracellular Vesicles Mediated RNA Therapy for Liver Fibrosis. Advanced Healthcare Materials 14 (2025) 2403068. https://doi.org/10.1002/ADHM.202403068 DOI: https://doi.org/10.1002/adhm.202403068

126. W. Li, C. Zhou, Y. Fu, T. Chen, X. Liu, Z. Zhang, T. Gong. Targeted delivery of hyaluronic acid nanomicelles to hepatic stellate cells in hepatic fibrosis rats. Acta Pharmaceutica Sinica B 10 (2020) 693-710. https://doi.org/10.1016/j.apsb.2019.07.003 DOI: https://doi.org/10.1016/j.apsb.2019.07.003

127. X. Wang, W. Zhang, S. Zeng, L. Wang, B. Wang. Collagenase Type I and Probucol-Loaded Nanoparticles Penetrate the Extracellular Matrix to Target Hepatic Stellate Cells for Hepatic Fibrosis Therapy. Acta Biomaterialia 175 (2024) 262-278. https://doi.org/10.1016/j.actbio.2023.12.027 DOI: https://doi.org/10.1016/j.actbio.2023.12.027

128. Y. Xiong, B. Wu, X. Guo, D. Shi, H. Xia, H. Xu, X. Liu. Galangin delivered by retinoic acid-modified nanoparticles targeted hepatic stellate cells for the treatment of hepatic fibrosis. RSC Advances 13 (2023) 10987-11001. https://doi.org/10.1039/d2ra07561j DOI: https://doi.org/10.1039/D2RA07561J

129. Y. Li, S. Pu, Q. Liu, R. Li, J. Zhang, T. Wu, L. Chen, H. Li, X. Yang, M. Zou, J. Xiao, W. Xie, J. He. An integrin-based nanoparticle that targets activated hepatic stellate cells and alleviates liver fibrosis. Journal of Controlled Release 303 (2019) 77-90. https://doi.org/10.1016/j.jconrel.2019.04.022 DOI: https://doi.org/10.1016/j.jconrel.2019.04.022

130. R. Li, J. Zhang, Q. Liu, Q. Tang, Q. Jia, Y. Xiong, J. He, Y. Li. CREKA-modified liposomes target activated hepatic stellate cells to alleviate liver fibrosis by inhibiting collagen synthesis and angiogenesis. Acta Biomaterialia 168 (2023) 484-496. https://doi.org/10.1016/j.actbio.2023.06.032 DOI: https://doi.org/10.1016/j.actbio.2023.06.032

131. Y. Zhang, Y. Li, T. Mu, N. Tong, P. Cheng. Hepatic stellate cells specific liposomes with the Toll-like receptor 4 shRNA attenuates liver fibrosis. Journal of Cellular and Molecular Medicine 25 (2021) 1299-1313. https://doi.org/10.1111/jcmm.16209 DOI: https://doi.org/10.1111/jcmm.16209

132. N.S. El-Mezayen, W.F. El-Hadidy, W.M. El-Refaie, Th.I. Shalaby, M.M. Khattab, A.S. El-Khatib. Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis. Journal of Controlled Release 266 (2017) 226-237. https://doi.org/10.1016/j.jconrel.2017.09.035 DOI: https://doi.org/10.1016/j.jconrel.2017.09.035

133. Y. Hao, K. Song, X. Tan, L. Ren, X. Guo, C. Zhou, H. Li, J. Wen, Y. Meng, M. Lin, Y. Zhang, H. Huang, L. Wang, W. Zheng. Reactive Oxygen Species-Responsive Polypeptide Drug Delivery System Targeted Activated Hepatic Stellate Cells to Ameliorate Liver Fibrosis. ACS Nano 16 (2022) 20739-20757. https://doi.org/10.1021/acsnano.2c07796 DOI: https://doi.org/10.1021/acsnano.2c07796

134. M.A. Morsy, A.B. Nair. Prevention of rat liver fibrosis by selective targeting of hepatic stellate cells using hesperidin carriers. International Journal of Pharmaceutics 552 (2018) 241-250. https://doi.org/10.1016/j.ijpharm.2018.10.003 DOI: https://doi.org/10.1016/j.ijpharm.2018.10.003

135. J. Wu, C. Qi, H. Wang, Q. Wang, J. Sun, J. Dong, G. Yu, Z. Gao, B. Zhang, G. Tian. Curcumin and berberine co-loaded liposomes for anti-hepatocellular carcinoma therapy by blocking the cross-talk between hepatic stellate cells and tumor cells. Frontiers in Pharmacology 13 (2022) 961788. https://doi.org/10.3389/fphar.2022.961788 DOI: https://doi.org/10.3389/fphar.2022.961788

136. R. Omar, J. Yang, S. Alrushaid, F.J. Burczynski, G.Y. Minuk, Y. Gong. Inhibition of BMP4 and Alpha Smooth Muscle Actin Expression in LX-2 Hepatic Stellate Cells by BMP4-siRNA Lipid Based Nanoparticle. Journal of Pharmacy and Pharmaceutical Sciences 21 (2019) 119-134. https://doi.org/10.18433/jpps29584 DOI: https://doi.org/10.18433/jpps29584

137. A. Ullah, K. Wang, P. Wu, D. Oupicky, M. Sun. CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFΒ-induced HSC-T6 cells activation. International Journal of Nanomedicine 14 (2019) 2927-2944. https://doi.org/10.2147/IJN.S171280 DOI: https://doi.org/10.2147/IJN.S171280

138. G. Valentino, C. Zivko, F. Weber, L. Brülisauer, P. Luciani, Synergy of phospholipid-drug formulations significantly deactivates profibrogenic human hepatic stellate cells. Pharmaceutics 11(12) (2019) 676. https://doi.org/10.3390/pharmaceutics11120676 DOI: https://doi.org/10.3390/pharmaceutics11120676

139. Q.Q. Fan, C.L. Zhang, J.B. Qiao, P.F. Cui, L. Xing, Y.K. Oh, H.L. Jiang. Extracellular matrix-penetrating nanodrill micelles for liver fibrosis therapy. Biomaterials 230 (2020) 119616. https://doi.org/10.1016/j.biomaterials.2019.119616 DOI: https://doi.org/10.1016/j.biomaterials.2019.119616

140. M. Wang, M. Zhang, L. Fu, J. Lin, X. Zhou, P. Zhou, P. Huang, H. Hu, Y. Han. Liver-targeted delivery of TSG-6 by calcium phosphate nanoparticles for the management of liver fibrosis. Theranostics 10 (2020) 36-49. https://doi.org/10.7150/thno.37301 DOI: https://doi.org/10.7150/thno.37301

141. J. Wang, Y. Ding, W. Zhou. Albumin self-modified liposomes for hepatic fibrosis therapy via SPARC-dependent pathways. International Journal of Pharmaceutics 574 (2020) 118940. https://doi.org/10.1016/j.ijpharm.2019.118940 DOI: https://doi.org/10.1016/j.ijpharm.2019.118940

142. C. Qi, D. Wang, X. Gong, Q. Zhou, X. Yue, C. Li, Z. Li, G. Tian, B. Zhang, Q. Wang, X. Wei, J. Wu. Co-Delivery of Curcumin and Capsaicin by Dual-Targeting Liposomes for Inhibition of aHSC-Induced Drug Resistance and Metastasis. ACS Applied Materials Interfaces 13 (2021) 16019-16035. https://doi.org/10.1021/acsami.0c23137 DOI: https://doi.org/10.1021/acsami.0c23137

143. S. Luo, Y. Yang, T. Zhao, R. Zhang, C. Fang, Y. Li, Z. Zhang, T. Gong. Albumin-Based Silibinin Nanocrystals Targeting Activated Hepatic Stellate Cells for Liver Fibrosis Therapy. ACS Applied Materials Interfaces 15 (2023) 7747-7758. https://doi.org/10.1021/acsami.2c19269 DOI: https://doi.org/10.1021/acsami.2c19269

144. D.G. You, B.H. Oh, V.Q. Nguyen, G.T. Lim, W. Um, J.M. Jung, J. Jeon, J.S. Choi, Y.C. Choi, Y.J. Jung, J. Lee, D.G. Jo, Y.W. Cho, J.H. Park. Vitamin A-coupled stem cell-derived extracellular vesicles regulate the fibrotic cascade by targeting activated hepatic stellate cells in vivo. Journal of Controlled Release 336 (2021) 285-295. https://doi.org/10.1016/j.jconrel.2021.06.031 DOI: https://doi.org/10.1016/j.jconrel.2021.06.031

145. Y. Tan, Z. Wang, R. Guo, X. Zhou, W. Zhang, M. Wu, C. Guo, H. Gao, X. Sun, Z. Zhang, T. Gong. Dual-Targeting Macrophages and Hepatic Stellate Cells by Modified Albumin Nanoparticles for Liver Cirrhosis Treatment. ACS Applied Materials Interfaces 16 (2024) 11239-11250. https://doi.org/10.1021/acsami.3c17670 DOI: https://doi.org/10.1021/acsami.3c17670

146. L. Sun, X. Luo, C. Zhou, Z. Zhou, M. Sun. Natural polysaccharide-based smart CXCR4-targeted nano-system for magnified liver fibrosis therapy. Chinese Chemical Letters 35 (2024) 108803. https://doi.org/10.1016/j.cclet.2023.108803 DOI: https://doi.org/10.1016/j.cclet.2023.108803

147. Z.C. Wu, X.Y. Liu, J.Y. Liu, J.S. Piao, M.G. Piao. Preparation of Betulinic Acid Galactosylated Chitosan Nanoparticles and Their Effect on Liver Fibrosis. International Journal of Nanomedicine 17 (2022) 4195-4210. https://doi.org/10.2147/IJN.S373430 DOI: https://doi.org/10.2147/IJN.S373430

148. X. Su, H. Zhong, Y. Zeng, Y. Zhang, B. Zhang, W. Guo, Q. Huang, Y. Ye. Dual-ligand-functionalized nanostructured lipid carriers as a novel dehydrocavidine delivery system for liver fibrosis therapy. Colloids and Surfaces B 246 (2025) 114376. https://doi.org/10.1016/J.COLSURFB.2024.114376 DOI: https://doi.org/10.1016/j.colsurfb.2024.114376

149. X. Niu, G. Chang, N. Xu, R. Li, B. Niu, R. Mao, S. Wang, G. Li, J. Jiang, L. Wang. Vitamin A-Integrated Cinnamaldehyde Nanoemulsion: A Nanotherapeutic Approach To Counteract Liver Fibrosis via Gut-Liver Axis Modulation. ACS Nano 19(10) (2025) 10433-10451. https://doi.org/10.1021/ACSNANO.5C00136 DOI: https://doi.org/10.1021/acsnano.5c00136

150. P. Hu, L. Su, Y. Wang, Y. Chen, X. Tian, Y. Qian. Targeting Liver Fibrosis with Nanoparticle Technology: The Dual-Drug Strategy for Hepatic Stellate Cell Activation Inhibition. ACS APplied Materials and Interfaces 17(17) (2025) 25071-25082. https://doi.org/10.1021/acsami.5c02796 DOI: https://doi.org/10.1021/acsami.5c02796

151. X. Su, H. Zhong, Y. Zeng, Y. Zhang, B. Zhang, W. Guo, Q. Huang, Y. Ye. Dual-ligand-functionalized nanostructured lipid carriers as a novel dehydrocavidine delivery system for liver fibrosis therapy. Colloids and Surfaces B 246 (2025) 114376. https://doi.org/10.1016/j.colsurfb.2024.114376 DOI: https://doi.org/10.1016/j.colsurfb.2024.114376

152. H. Liu, Y. Qi, L. Wang, Y. Zhang, H. Chen, Y. Zhao, H. Min, G. Nie, H. Liang. Lysosome-Targeting Nanochimeras Attenuating Liver Fibrosis by Interconnected Transforming Growth Factor-β Reduction and Activin Receptor-Like Kinase 5 Degradation. ACS Nano 19 (2025) 25645-25661. https://doi.org/10.1021/acsnano.5c00985 DOI: https://doi.org/10.1021/acsnano.5c00985

153. K. Togami, Y. Kanehira, Y. Nakamura, H. Ishii, R. Abe, A. Yamamoto, K. Takehara, M. Yasuda, H. Tada, S. Chono. Pirfenidone encapsulated in succinylated gelatin-coated liposomes exhibits sustained antifibrotic effects in vitro models of renal, pulmonary, and hepatic fibrosis. Journal of Pharmacetical Sciences 114 (2025) 103819. https://doi.org/10.1016/j.xphs.2025.103819 DOI: https://doi.org/10.1016/j.xphs.2025.103819

154. X. Liu, C. Fang, H. Yu, L. Huang, J. Feng, S. Luo, L. Song, M. Wu, Y. Tan, J. Dong, T. Gong, P. Xiao. Chondroitin Sulfate-Based Imatinib Nanoparticles Targeting Activated Hepatic Stellate Cells Against Hepatic Fibrosis. Pharmaceutics 17 (2025) 351. https://doi.org/10.3390/pharmaceutics17030351 DOI: https://doi.org/10.3390/pharmaceutics17030351

155. M. Lu, Z. Dai, Y. Lin, C. Sun, S. Li, Z. Guo, Y. Liu, X. Liu, S. Li, R. Liu, B. Xu, H. Lei. Co-Assembled Nanoparticles Comprising Sorafenib and Hederagenin Derivative for Enhanced Anti-Hepatic Fibrosis Activity. International Journal of Nanomedicine 20 (2025) 9135-9153. https://doi.org/10.2147/IJN.S512005 DOI: https://doi.org/10.2147/IJN.S512005

156. R. Yang, L. Yang, N. Zhang, Y. Wan, S. Chen, Y. Xiao, X. Liang, S. Yang, Y. Zhong, D. Huang, W. Chen, B. Zhao. Targeted delivery of polymeric NO-donor micelles to hepatic stellate cells for restoration of liver function and inhibition of hepatic fibrosis. Journal of Controlled Release 379 (2025) 466-477. https://doi.org/10.1016/j.jconrel.2025.01.036 DOI: https://doi.org/10.1016/j.jconrel.2025.01.036

157. M.K. Mohsen, S.A.E. azm Diab, A.N. Shafik, A.H. Osman, M.J. Naguib, A.M. Kamel, M.N. Mehesen. Sofosbuvir’s hepatoprotective efficacy in rats is enhanced by encapsulating in taurocholate-stabilized galactose-anchored bilosomes. Future Journal of Pharmaceutical Sciences 11 (2025) 21. https://doi.org/10.1186/s43094-025-00775-w DOI: https://doi.org/10.1186/s43094-025-00775-w

158. A. Mokhtariye, J. Varshosaz, A. Mohammadalipour, M. Hashemnia, M.R. Mofid. Xanthosomes loaded with recombinant TMEM219 for targeting IGFBP-3: A novel approach for targeted drug delivery to ameliorate liver fibrosis. Life Sciences 377 (2025) 123748. https://doi.org/10.1016/j.lfs.2025.123748 DOI: https://doi.org/10.1016/j.lfs.2025.123748

159. R. Li, Y. Tai, X. Zhang, Z. Liu, H. Si, D. Kong, L. Zhao, J. Li, A.C. Midgley. Tissue-Microenvironment-Responsive Self-Assembling Peptide Nanoshells Boost Pirfenidone Efficacy in the Treatment of Liver Fibrosis. Advanced Healthcare Materials 14 (2025) 2500101. https://doi.org/10.1002/adhm.202500101 DOI: https://doi.org/10.1002/adhm.202500101

160. X. Xiang, Y. Shao, L. Xiang, Q. Jiao, W. Zhang, Y. Qin, Y. Chen. Suppression of Liver Fibrogenesis with Photothermal Sorafenib Nanovesicles via Selectively Inhibiting Glycolysis and Amplification of Active HSCs. Molecular Pharmaceutics 22 (2025) 1939-1957. https://doi.org/10.1021/acs.molpharmaceut.4c01135 DOI: https://doi.org/10.1021/acs.molpharmaceut.4c01135

161. X. Liu, X. Mu, Y. Wang, Z. Liu, Y. Li, J. Lan, S. Feng, S. Wang, Q. Zhao. Metal-based mesoporous polydopamine with dual enzyme-like activity as biomimetic nanodrug for alleviating liver fibrosis. Journal of Colloid and Interface Science 684 (2025) 586-599. https://doi.org/10.1016/j.jcis.2025.01.081 DOI: https://doi.org/10.1016/j.jcis.2025.01.081

Downloads

Published

04-08-2025

Issue

Vol. 13 No. 4 (2025)

Section

Pharmaceutics

License

Copyright (c) 2025 Alka Singh, Ansab Akthar, Prashant Shukla

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Exploring hepatic stellate cell-driven fibrosis: therapeutic advances and future perspectives: Review article. (2025). ADMET and DMPK, 13(4), Article 2874. https://doi.org/10.5599/admet.2874